Paget’s disease in an Omani: Long-term improvement following a single injection of zoledronic acid

Omayma Elshafie, Nooralddin Alsaffi, Samir Hussain, Nicholas Woodhouse

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Paget’s disease of bone is a patchy skeletal disorder characterized by an increase in bone resorption and formation in the affected areas. It affects up to 3% of individuals of Anglo- Saxon origin over the age of 40 years but is rare in Arabs. Although most patients are asymptomatic, a variety of symptoms and complications may develop directly from bone involvement or secondarily to compression by bone expansion and increased blood flow. The disease can be treated by using medications that inhibit bone resorption, such as calcitonin and the bisphosphonates. Here we describe the case of an Omani patient with the disease, involving the skull, spine, pelvis, and tibia. He presented to the endocrine clinic in Sultan Qaboos University Hospital with a six-year history of headache, bone pain, progressive skull enlargement, and left-sided deafness. His alkaline phosphatase (ALP) level was 1500 U/L. His disease responded gradually to six months of subcutaneous and nasal calcitonin followed by a single 5 mg intravenous injection of zoledronic acid. This resulted in a further progressive reduction of his bone pain, skull size, and improvement in his hearing, as well as normalization of his serum ALP levels after one-year. This effect has been sustained for 3 years.

Original languageEnglish
Pages (from-to)146-149
Number of pages4
JournalOman Medical Journal
Volume31
Issue number2
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

zoledronic acid
Skull
Bone and Bones
Injections
Calcitonin
Bone Resorption
Alkaline Phosphatase
Osteitis Deformans
Pain
Diphosphonates
Deafness
Pelvis
Tibia
Nose
Osteogenesis
Intravenous Injections
Hearing
Headache
Spine
Serum

Keywords

  • Alkaline phosphatase
  • Calcitonin
  • Paget’s disease of bone
  • Zoledronic acid

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Paget’s disease in an Omani : Long-term improvement following a single injection of zoledronic acid. / Elshafie, Omayma; Alsaffi, Nooralddin; Hussain, Samir; Woodhouse, Nicholas.

In: Oman Medical Journal, Vol. 31, No. 2, 01.03.2016, p. 146-149.

Research output: Contribution to journalArticle

Elshafie, Omayma ; Alsaffi, Nooralddin ; Hussain, Samir ; Woodhouse, Nicholas. / Paget’s disease in an Omani : Long-term improvement following a single injection of zoledronic acid. In: Oman Medical Journal. 2016 ; Vol. 31, No. 2. pp. 146-149.
@article{162ed1930f16486a825dd0384660b2e2,
title = "Paget’s disease in an Omani: Long-term improvement following a single injection of zoledronic acid",
abstract = "Paget’s disease of bone is a patchy skeletal disorder characterized by an increase in bone resorption and formation in the affected areas. It affects up to 3{\%} of individuals of Anglo- Saxon origin over the age of 40 years but is rare in Arabs. Although most patients are asymptomatic, a variety of symptoms and complications may develop directly from bone involvement or secondarily to compression by bone expansion and increased blood flow. The disease can be treated by using medications that inhibit bone resorption, such as calcitonin and the bisphosphonates. Here we describe the case of an Omani patient with the disease, involving the skull, spine, pelvis, and tibia. He presented to the endocrine clinic in Sultan Qaboos University Hospital with a six-year history of headache, bone pain, progressive skull enlargement, and left-sided deafness. His alkaline phosphatase (ALP) level was 1500 U/L. His disease responded gradually to six months of subcutaneous and nasal calcitonin followed by a single 5 mg intravenous injection of zoledronic acid. This resulted in a further progressive reduction of his bone pain, skull size, and improvement in his hearing, as well as normalization of his serum ALP levels after one-year. This effect has been sustained for 3 years.",
keywords = "Alkaline phosphatase, Calcitonin, Paget’s disease of bone, Zoledronic acid",
author = "Omayma Elshafie and Nooralddin Alsaffi and Samir Hussain and Nicholas Woodhouse",
year = "2016",
month = "3",
day = "1",
doi = "10.5001/omj.2016.28",
language = "English",
volume = "31",
pages = "146--149",
journal = "Oman Medical Journal",
issn = "1999-768X",
publisher = "Oman Medical Specialty Board",
number = "2",

}

TY - JOUR

T1 - Paget’s disease in an Omani

T2 - Long-term improvement following a single injection of zoledronic acid

AU - Elshafie, Omayma

AU - Alsaffi, Nooralddin

AU - Hussain, Samir

AU - Woodhouse, Nicholas

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Paget’s disease of bone is a patchy skeletal disorder characterized by an increase in bone resorption and formation in the affected areas. It affects up to 3% of individuals of Anglo- Saxon origin over the age of 40 years but is rare in Arabs. Although most patients are asymptomatic, a variety of symptoms and complications may develop directly from bone involvement or secondarily to compression by bone expansion and increased blood flow. The disease can be treated by using medications that inhibit bone resorption, such as calcitonin and the bisphosphonates. Here we describe the case of an Omani patient with the disease, involving the skull, spine, pelvis, and tibia. He presented to the endocrine clinic in Sultan Qaboos University Hospital with a six-year history of headache, bone pain, progressive skull enlargement, and left-sided deafness. His alkaline phosphatase (ALP) level was 1500 U/L. His disease responded gradually to six months of subcutaneous and nasal calcitonin followed by a single 5 mg intravenous injection of zoledronic acid. This resulted in a further progressive reduction of his bone pain, skull size, and improvement in his hearing, as well as normalization of his serum ALP levels after one-year. This effect has been sustained for 3 years.

AB - Paget’s disease of bone is a patchy skeletal disorder characterized by an increase in bone resorption and formation in the affected areas. It affects up to 3% of individuals of Anglo- Saxon origin over the age of 40 years but is rare in Arabs. Although most patients are asymptomatic, a variety of symptoms and complications may develop directly from bone involvement or secondarily to compression by bone expansion and increased blood flow. The disease can be treated by using medications that inhibit bone resorption, such as calcitonin and the bisphosphonates. Here we describe the case of an Omani patient with the disease, involving the skull, spine, pelvis, and tibia. He presented to the endocrine clinic in Sultan Qaboos University Hospital with a six-year history of headache, bone pain, progressive skull enlargement, and left-sided deafness. His alkaline phosphatase (ALP) level was 1500 U/L. His disease responded gradually to six months of subcutaneous and nasal calcitonin followed by a single 5 mg intravenous injection of zoledronic acid. This resulted in a further progressive reduction of his bone pain, skull size, and improvement in his hearing, as well as normalization of his serum ALP levels after one-year. This effect has been sustained for 3 years.

KW - Alkaline phosphatase

KW - Calcitonin

KW - Paget’s disease of bone

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=84961252785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961252785&partnerID=8YFLogxK

U2 - 10.5001/omj.2016.28

DO - 10.5001/omj.2016.28

M3 - Article

AN - SCOPUS:84961252785

VL - 31

SP - 146

EP - 149

JO - Oman Medical Journal

JF - Oman Medical Journal

SN - 1999-768X

IS - 2

ER -